NO20081364L - Amorfe faste dispersjoner - Google Patents

Amorfe faste dispersjoner

Info

Publication number
NO20081364L
NO20081364L NO20081364A NO20081364A NO20081364L NO 20081364 L NO20081364 L NO 20081364L NO 20081364 A NO20081364 A NO 20081364A NO 20081364 A NO20081364 A NO 20081364A NO 20081364 L NO20081364 L NO 20081364L
Authority
NO
Norway
Prior art keywords
amorphous solid
solid dispersions
blindol
pyridazino
acetamide
Prior art date
Application number
NO20081364A
Other languages
English (en)
Norwegian (no)
Inventor
Khawla Abdullah Abu-Izza
Irwin C Jacobs
John D Higgins
Micael Guillot
Nancy M Franson
William L Rocco
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37499538&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081364(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of NO20081364L publication Critical patent/NO20081364L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO20081364A 2005-08-29 2008-03-14 Amorfe faste dispersjoner NO20081364L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71215005P 2005-08-29 2005-08-29
PCT/US2006/033022 WO2007027494A2 (en) 2005-08-29 2006-08-24 Morphous solid dispersions of 7-chloro-n,n, 5-trimethyl-4-oxo-3-phenyl-3, 5,-dihydro-4h-pyridazino [4, 5-b] indole-1-acetamide

Publications (1)

Publication Number Publication Date
NO20081364L true NO20081364L (no) 2008-04-03

Family

ID=37499538

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081364A NO20081364L (no) 2005-08-29 2008-03-14 Amorfe faste dispersjoner

Country Status (30)

Country Link
US (1) US7713548B2 (sr)
EP (1) EP1926476B1 (sr)
JP (1) JP5026426B2 (sr)
KR (1) KR20080061354A (sr)
CN (1) CN101272767B (sr)
AR (1) AR055615A1 (sr)
AU (1) AU2006285111B8 (sr)
BR (1) BRPI0615609A2 (sr)
CA (1) CA2619438A1 (sr)
CR (1) CR9750A (sr)
DK (1) DK1926476T3 (sr)
EA (1) EA015715B1 (sr)
EC (1) ECSP088203A (sr)
ES (1) ES2414434T3 (sr)
HN (1) HN2008000360A (sr)
HR (1) HRP20130533T1 (sr)
IL (1) IL189587A (sr)
MA (1) MA29783B1 (sr)
ME (1) ME01560B (sr)
NO (1) NO20081364L (sr)
NZ (1) NZ566313A (sr)
PL (1) PL1926476T3 (sr)
PT (1) PT1926476E (sr)
RS (1) RS52914B (sr)
SI (1) SI1926476T1 (sr)
TN (1) TNSN08069A1 (sr)
TW (1) TWI398250B (sr)
UA (1) UA93517C2 (sr)
WO (1) WO2007027494A2 (sr)
ZA (1) ZA200801893B (sr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
EP2674428B1 (en) 2006-04-07 2016-04-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
CN101702878B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
CA2717326C (en) * 2008-03-11 2018-10-23 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
RU2011110241A (ru) * 2008-08-18 2012-09-27 САНОФИ-АВЕНТИС Ю.Эс. ЭлЭлСи (US) СПОСОБ ПОЛУЧЕНИЯ ПОЛИМОРФА 7-ХЛОР-N,N,5-ТРИМЕТИЛ-4-ОКСО-3-ФЕНИЛ-3,5-ДИГИДРО-4Н-ПИРИДАЗИНО[4,5-b]ИНДОЛ-1-АЦЕТАМИДА
SI2826776T1 (sl) * 2010-03-25 2021-02-26 Vertex Pharmaceuticals Incorporated Trdna disperzija amorfne oblike (R)-1(2,2-difluorobenzo(D)(1,3)dioksol-5-il)-N-(1-(2,3-dihidroksipropil) -6-fluoro-2-(1-hidroksi-2-metilpropan-2-il)-1H-indol-5-il)- ciklopropankarboksamida
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
US9801855B2 (en) 2012-03-07 2017-10-31 National Institute Of Pharmaceutical Education And Research (Niper) Nanocrystalline solid dispersion compositions and process of preparation thereof
KR101986683B1 (ko) 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
CN105493092A (zh) * 2013-08-30 2016-04-13 慧与发展有限责任合伙企业 实时移动与模式分布的比较
CN106232144B (zh) * 2014-03-18 2019-12-06 武田药品工业株式会社 固体分散体
RU2744460C2 (ru) 2014-04-15 2021-03-09 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости
EP4049660B1 (en) 2016-02-29 2025-02-19 F. Hoffmann-La Roche AG Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
AU2018296476B2 (en) * 2017-07-04 2023-11-02 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition and method for preparing same
JP2025008679A (ja) * 2023-07-05 2025-01-20 学校法人 名城大学 非晶質性化有機化合物を含む複合粒子の製造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091381A (en) * 1991-04-12 1992-02-25 Biomeasure, Inc. 2H-1,3,4-benzotriazepin-2-ones
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
FR2766823B1 (fr) 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
ES2306646T3 (es) 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
EP1120109A3 (en) * 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
FR2829939B3 (fr) * 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
WO2005034999A2 (en) * 2003-10-10 2005-04-21 Bvm Holding Co. Composition comprising association complex of a pharmaceutical and a poloxamer

Also Published As

Publication number Publication date
JP2009506114A (ja) 2009-02-12
EP1926476A2 (en) 2008-06-04
ECSP088203A (es) 2008-06-30
WO2007027494A3 (en) 2007-08-02
EA200800713A1 (ru) 2008-10-30
US7713548B2 (en) 2010-05-11
PL1926476T3 (pl) 2013-08-30
TW200727902A (en) 2007-08-01
KR20080061354A (ko) 2008-07-02
SI1926476T1 (sl) 2013-07-31
RS52914B (sr) 2014-02-28
UA93517C2 (en) 2011-02-25
BRPI0615609A2 (pt) 2011-05-24
ME01560B (me) 2014-04-20
DK1926476T3 (da) 2013-07-01
EA015715B1 (ru) 2011-10-31
IL189587A (en) 2012-12-31
CR9750A (es) 2008-06-18
AU2006285111B8 (en) 2012-05-17
ES2414434T3 (es) 2013-07-19
WO2007027494A2 (en) 2007-03-08
IL189587A0 (en) 2008-08-07
PT1926476E (pt) 2013-07-10
NZ566313A (en) 2011-04-29
HK1124785A1 (en) 2009-07-24
CN101272767A (zh) 2008-09-24
AU2006285111A1 (en) 2007-03-08
JP5026426B2 (ja) 2012-09-12
EP1926476B1 (en) 2013-04-10
CA2619438A1 (en) 2007-03-08
HRP20130533T1 (en) 2013-07-31
AR055615A1 (es) 2007-08-29
HN2008000360A (es) 2011-05-31
AU2006285111B2 (en) 2012-04-26
ZA200801893B (en) 2009-08-26
MA29783B1 (fr) 2008-09-01
CN101272767B (zh) 2012-08-29
TWI398250B (zh) 2013-06-11
US20080160080A1 (en) 2008-07-03
TNSN08069A1 (en) 2009-07-14

Similar Documents

Publication Publication Date Title
NO20081364L (no) Amorfe faste dispersjoner
UY3402Q (es) Diseno de tractor
WO2006042138A8 (en) Systems and methods for ex-vivo organ care
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
TW200732349A (en) Anti-OX40L antibodies and methods using same
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
BRPI0811046A2 (pt) Composto de hidrazida heterocíclica e uso pesticida do mesmo.
TW200737268A (en) Ion sources, systems and methods
TW200717389A (en) Luminance adjustment
WO2009042114A3 (en) Phenazine derivatives and uses thereof
MX2010002028A (es) Metodos y composiciones para modular celulas t.
WO2007120334A3 (en) Methods and compositions for targeting polyubiquitin
TW200715634A (en) Stable organic devices
TW200715969A (en) Fungicidal active-compound combination
GB2464417A (en) Security deterrent mark and methods of forming the same
BRPI0814989A8 (pt) Derivado de triazolilpiridina cetona, e herbicidas
WO2006091848A3 (en) Isolated bis-linezolid, preparation thereof, and its use as a reference standard
MY143382A (en) Aqueous rodenticide formulations
WO2007067729A3 (en) Microbial vaccine and vaccine vector
MY139010A (en) 6-azo-5, 5'-dihydroxy -7,7'-disulfo-2-2'-dinaphthylamine derivatives
TW200724152A (en) Oligopeptide, derivative thereof, and pharmaceutical composition comprising the same
ATE434604T1 (de) Amorphes tamsulosin-hydrochlorid
CY1114124T1 (el) Αμορφες στερεες διασπορες της 7-χλωρο-ν,ν,5-τριμεθυλ-4-οξο-3-φαινυλ-3,5- διϋδρο-4η-πυριδαζινο[4,5-β]ινδολη-1-ακεταμιδης
Азімов et al. Êîðîòê³ â³äîìîñò³ Êîðîòê³ â³äîìîñò³ ïðî àâòîð³â ïðî àâòîð³â
AU307553S (en) Agricultural sprayer intake

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application